查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466392

癌症/肿瘤分析市场：按技术、生物标记类型、癌症类型、应用划分 - 2024-2030 年全球预测

Cancer/Tumor Profiling Market by Technology (Immunoassays, In-Situ Hybridization, Mass Spectrometry), Biomarker Type (Genomic Biomarker, Protein Biomarker), Cancer Type, Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年癌症/肿瘤分析市场规模预计为107.9亿美元，预计2024年将达到127.7亿美元，2030年将达到359.4亿美元，复合年增长率为18.74%。

癌症/肿瘤分析是一种分析肿瘤内特定蛋白质、基因和其他分子并提供有关遗传或分子变化（例如基因突变）的资讯的测试。肿瘤分析是肿瘤学家广泛使用的技术，用于确定患者的肿瘤途径是否与现有的标靶治疗相容。生物标记在癌症患者治疗中的加速使用、对定制癌症治疗的日益偏好以及政府和国际组织对癌症诊断开发的日益关注我们正在支持癌症/肿瘤分析技术的普及。然而，癌症/肿瘤分析工具和服务的高资本投资以及生物标记的低发现核准率正在阻碍市场开拓。然而，随着次世代定序的普及、肿瘤分析的改进以及照护现场检测技术的扩展，预计未来几年的使用量将激增。

主要市场统计
基准年[2023] 107.9亿美元
预测年份 [2024] 127.7亿美元
预测年份 [2030] 359.4亿美元
复合年增长率（%） 18.74%

采用次世代定序仪(NGS) 技术研究各种癌症的基因变化

免疫检测在癌症肿瘤分析市场的技术领域占据主导地位，因为它们越来越多地应用于大规模肿瘤分析，因为它们有助于确定样本中分析物的存在和浓度。萤光原位杂合技术原位杂合反应(FISH) 和显色原位杂合反应(CISH)，利用固定在染色体或玻片上的标记互补 DNA 或 RNA 链来定位特定的 DNA 或 RNA 序列。一部分（原位）。 FISH 分析比传统方法更省时，并且可以轻鬆检查染色体微缺失、扩增和易位。基于质谱的研究越来越多地用于癌症研究，以检测蛋白质组和代谢组的细微变化。相较之下，微阵列广泛用于了解癌细胞的遗传和表观遗传组成，并已被用来识别癌细胞中的微小遗传变化。次世代定序仪（NGS）的发展可以有效地探索各种癌症的遗传改变，并识别多种遗传或表观遗传突变，从而产生新的生物标记物，对疾病的早期诊断有所帮助。聚合酵素链锁反应(PCR) 用于检查基因和染色体的特定变化，有助于发现和诊断遗传状况和疾病，例如癌症。此外，诊断影像和生化过程的技术进步能够及早发现转移性病变，这可能会提高癌症治疗的成功率。

生物标记的类型：基因生物标誌物用于测量基因表现、基因功能和基因调控。

基因生物标誌物可称为基因表现、基因功能和基因调控的测量，测试显示一个人的癌症具有假定的肾小球滤过率（EGFR）基因突变，可以用 EGFR 抑制剂治疗。治疗方法是否正在临床试验中进行测试。理想的癌症生物标记可以是在患者血液或尿液中很容易检测到的蛋白质或蛋白质片段，健康患者除外。此外，许多癌症生物标记在体内的作用不同，对治疗的反应也不同。这些癌症生物标记还可以包括基因突变（变化）、基因重排、基因的额外拷贝、基因缺陷和几种其他分子。

癌症类型：前列腺癌癌症分析用于预测建模和临床风险分层的广泛偏好

癌症/肿瘤分析已成为乳癌多个层面疾病管理的重要组成部分。基因检测可识别有恶性家族病史的患者的遗传性癌症综合征，有助于成功预防乳癌。大肠直肠癌 (CRC) 的分子分析具有提供有关癌症病理学和标靶治疗的重要资讯的优点。儘管化疗仍然是治疗的支柱，但随着对其异质性和分子蓝图的了解，转移性大肠直肠癌 (mCRC) 治疗的模式正在改变。可以检测肺癌的常见基因突变，例如估计肾小球滤过率（EGFR）、RET、MET、BRAF和间变性淋巴瘤激酶（ALK），从而为患者提供标靶治疗。基于基因表现(GEP) 的皮肤黑色素瘤 (CM) 分子预测测试非常敏感，并且具有预测生物学行为的潜力。此外，前列腺癌的癌症/肿瘤分析最近已成为预测建模和临床风险分层的可靠方法。前列腺肿瘤的综合基因组分析提供了全面的资讯和新发现，将在精准医学的新时代提高对疾病的理解。

应用越来越多地使用癌症/肿瘤分析来开发精准医学，以缩短癒合和恢復时间

癌症/肿瘤分析将透过识别治疗标靶和分子生物标记、显着改善许多常见和罕见肿瘤的结果以及个人化癌症治疗来极大地推进临床肿瘤学。癌症/肿瘤分析通常用于开发针对患者基因组成的精准医疗，并缩短癒合和恢復时间。新技术和复杂技术的应用以及生物标记的临床应用将提升生物标记的发现和开发，并改善诊断、预后和疾病监测。研究人员正在寻求更精确、更有针对性的技术来简化癌症治疗，导致快速诊断提供者寻求高度复杂的癌症分析方法。基于基因组的预后生物标记用于预测临床阶段几种癌症类型的预后，也可用于药物和治疗方法的开发。癌症/肿瘤分析也可用于癌症筛检，有助于早期发现、早期管理和可能治癒癌症。此外，癌症/肿瘤分析提供了灵敏且准确的生物标记检测，并为非侵入性疾病诊断和治疗反应监测提供了可靠的方法。

区域洞察

北美、欧盟、海湾合作委员会和亚太地区已开发国家的癌症/肿瘤分析市场格局具有突出的倡议参与企业和完善的监管框架，以减轻癌症负担，同时改善患者照护。 。随着癌症诊断投资的不断增加，癌症分析逐渐在世界各地的新兴经济体中受到关注。据美国癌症协会称，预计 2023 年美国将有约 190 万名新癌症患者被诊断出来，这增加了癌症分析的需求。在北欧和西欧国家，生物标记测试的采用率和可用性要高得多，反映出医疗保健方面的投资增加。国际市场相关人员正在与美国和欧洲国家的技术提供者合作，为癌症诊断、分析和治疗方法的进步做出贡献。此外，正在进行的宣传活动和癌症意识计划强调了亚洲国家进行癌症/肿瘤分析的必要性。

FPNV定位矩阵

FPNV 定位矩阵对于评估癌症/肿瘤分析市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对癌症/肿瘤分析市场中供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.癌症/肿瘤分析市场的市场规模和预测是多少？

2.在癌症/肿瘤分析市场的预测期间内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.癌症/肿瘤分析市场的技术趋势和法规结构是什么？

4.癌症/肿瘤分析市场主要供应商的市场占有率为何？

5. 进入癌症/肿瘤分析市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 在癌症患者的治疗中更多地采用生物标记
      • 各国政府和国际组织为开发癌症诊断方法所做的努力
      • 人们对癌症治疗中的个人化医疗越来越感兴趣
    • 抑制因素
      • 对癌症/肿瘤分析设备和服务的大量资本投资
    • 机会
      • 次世代定序的出现和肿瘤分析的进展
      • 改进照护现场诊断技术以改善癌症检测
    • 任务
      • 生物标誌物的发现率和核准较低
  • 市场区隔分析
    • 技术：使用次世代定序(NGS) 寻找各种癌症的基因突变
    • 生物标记的类型：基因生物标誌物用于测量基因表现、基因功能和基因调控。
    • 癌症类型：广泛推荐前列腺癌的癌症分析以用于预测模型和临床风险分层
    • 应用：在开发精准医学中增加使用癌症/肿瘤分析来缩短癒合和恢復时间
  • 市场趋势分析
    • 政府在癌症诊断方面的措施以及癌症/肿瘤分析解决方案的快速进展
    • 癌症发生率的上升和癌症研究的进步正在推动亚太地区对新的癌症/肿瘤分析的需求。
    • 全部区域越来越多地采用精准药物和基因分析解决方案来克服癌症负担
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析

第六章癌症/肿瘤分析市场：依技术分类

  • 免疫学测试
  • 原位杂交
  • 质谱
  • 微阵列
  • 次世代定序
  • 聚合酵素链锁反应

第 7 章按生物标记类型分類的癌症/肿瘤分析市场

  • 基因生物标誌物
  • 蛋白质生物标记

第 8 章按癌症类型分類的癌症/肿瘤分析市场

  • 乳癌
  • 大肠直肠癌
  • 肺癌
  • 黑色素瘤癌症
  • 摄护腺癌

第九章癌症/肿瘤分析市场：依应用分类

  • 生物标记发现
  • 临床应用
  • 诊断
  • 个人化医疗
  • 预言
  • 调查
  • 筛分
  • 治疗和监测

第10章美洲癌症/肿瘤分析市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太癌症/肿瘤分析市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的癌症/肿瘤分析市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 安捷伦与 NCCS 签署研究合作协议，推动新加坡亚洲常见癌症的基因组分析
    • Sophia Genetics 与安捷伦合作开发癌症分析产品
    • Point32Health 和 Foundation Medicine 扩大了晚期癌症患者全面基因组分析的范围
    • 协同效应 Laboratories 选择 SOPHiA GENETICS 技术用于新的癌症分析解决方案
    • Exact Sciences 在美国推出 OncoExTra 癌症治疗选择测试
    • Caris Life Sciences 筹集了 4 亿美元，使总资金筹措接近 20 亿美元
    • Prenetics 旗下 ACT Genomics 的 ACTOnco 获得 FDA 批准
    • 安捷伦宣布收​​购用于癌症研究的高性能 NGS靶向序列捕获工作流程开发商 Avida Biomed
    • Prenetics 收购 ACT Genomics
    • 罗氏首个伴同性诊断获得 FDA核准，用于识别符合 Enhertu 资格的 HER2 低转移性乳癌患者
    • CDC 拨款 2.15 亿美元推动癌症登月目标

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-374DB5A06C7F

[199 Pages Report] The Cancer/Tumor Profiling Market size was estimated at USD 10.79 billion in 2023 and expected to reach USD 12.77 billion in 2024, at a CAGR 18.74% to reach USD 35.94 billion by 2030.

Cancer/tumor profiling is a laboratory method that analyzes specific proteins, genes, and other molecules in a tumor to provide information about any genetic or molecular changes, such as gene mutations. Tumor profiling is the technology that oncologists widely use to determine if the pathways of a patient's tumor match up with available targeted treatments. Accelerated use of biomarkers in the treatment of cancer patients and increasing preference for customized cancer treatments coupled with government and international organization's efforts to develop cancer diagnosis methods support the widespread use of cancer/tumor profiling technologies. On the other hand, high capital investment in cancer/tumor profiling tools and services and low biomarker discovery-to-approval ratio hinders market development. However, the spread of next-generation sequencing, tumor profiling improvements, and point-of-care cancer detection technology expansion is expected to surge their use in the coming years.

KEY MARKET STATISTICS
Base Year [2023] USD 10.79 billion
Estimated Year [2024] USD 12.77 billion
Forecast Year [2030] USD 35.94 billion
CAGR (%) 18.74%

Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers

Immunoassays dominate the technology segment of the cancer tumor profiling market owing to rising applications in conducting tumor profiling on a large scale, as they aid in measuring the presence and concentration of analytes in a sample. In situ hybridization (ISH), including fluorescence in-situ hybridization (FISH) and chromogenic in situ hybridization (CISH), uses labeled complementary DNA or RNA strands to localize a specific DNA or RNA sequence on a chromosome or section of tissue (in-situ) fixed on a slide. FISH profiling is less time-consuming than conventional approaches and assists in easy chromosomal microdeletion, amplification, and translocation. Mass spectrometry-based cancer/tumor profiling is increasingly used in cancer research to detect subtle changes in proteome and metabolome. In contrast, microarrays are widely used to understand cancer cells' genetic and epigenetic makeup, and they are utilized to identify small genetic changes in tumor cells. The development of next-generation sequencing (NGS) helps in effectively exploring genetic alterations in various cancers and identifying several genetic or epigenetic variants to develop new biomarkers for early diagnosis of the disease. Polymerase chain reaction (PCR) is used to look for specific changes in a gene or chromosome, which helps find and diagnose a genetic condition or a disease, such as cancer. Moreover, technological advances in imaging and biochemical processes that allow earlier detection of a metastatic lesion could yield higher success rates in cancer therapy.

Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation

Genomic biomarkers can be termed as the measurement of the expression of a gene, the gene function, or the gene regulation, and testing can determine whether someone's cancer has an estimated glomerular filtration rate (EGFR) gene mutation that can be treated with an EGFR inhibitor and also helps study a new cancer treatment in a clinical trial. An ideal cancer biomarker can be a protein or protein fragment that is easy to detect in the patient's blood or urine except for a healthy patient. In addition, there are many cancer biomarkers, and they separately work within the body and react differently to treatments. These cancer biomarkers can also include gene mutations (changes), gene rearrangements, extra copies of genes, missing genes, and several other molecules.

Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification

Cancer/tumor profiling has become an integral part of disease management on multiple levels for breast cancer. Genetic testing identifies hereditary cancer syndromes in patients with a family history of malignancies and contributes to successful breast cancer prevention. Molecular profiling of colorectal cancer (CRC) has the advantage of providing essential information on the pathogenesis of cancer and also about the targeted therapy. The landscape of metastatic CRC (mCRC) treatment is changing with an understanding of its heterogeneity and molecular blueprint, although chemotherapy remains the backbone of treatment. Common genetic mutations in lung cancer, such as estimated glomerular filtration rate (EGFR), RET, MET, BRAF, and anaplastic lymphoma kinase (ALK), can be detected, which leads to offering targeted therapy to the patient. Molecular predictive tests based on gene expression profiling (GEP) of cutaneous melanoma (CM) are susceptible and have the potential to predict biological behavior. Moreover, cancer/tumor profiling of prostate cancer has more recently emerged as a reliable method for predictive modeling and clinical risk stratification. Integrative genomic profiling of prostate tumors has provided comprehensive information and novel discoveries that improve understanding of the disease in the new era of precision medicine.

Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time

Cancer/tumor profiling has significantly advanced clinical oncology by identifying therapeutic targets and molecular biomarkers, guiding the personalization of cancer treatment with remarkably improved outcomes for numerous common and rare tumor entities. Cancer/tumor profiling is normally used in developing precision medicine that suits a patient's genetic makeup to improve healing and recovery time. The upgradation of biomarker discovery and development with the application of new and complex technologies and more clinical applications of biomarkers improves diagnosis, prognosis, and disease monitoring. Researchers are touting more precision-based and targeted techniques to streamline cancer treatment, which propels rapid diagnostics providers to seek highly sophisticated cancer profiling approaches. Genome-based prognostic biomarkers are used in the prognosis of several cancer types at clinical stages and also help develop drugs and therapies. Cancer/tumor profiling is also helpful in cancer screening and can help in early detection, management, and, potentially, curing cancer. In addition, cancer/tumor profiling offers the sensitive and accurate detection of biomarkers and has a reliable approach for noninvasive disease diagnosis and treatment response monitoring.

Regional Insights

Cancer/tumor profiling market landscape in North America, the EU, GCC, and developed countries across the Asia-Pacific region are highly advanced due to prominent market players and well-established regulatory frameworks and initiatives launched by the governments to reduce cancer burden while improving patient care. Cancer profiling is gradually gaining prominence in developing economies worldwide as investments in cancer diagnostics continue to rise. According to the American Cancer Society, approximately 1.9 million new cancer cases are anticipated to be diagnosed in the United States in 2023, bolstering the need for cancer profiling. Northern and Western European countries observe considerably high use and availability of biomarker testing procedures, refiecting their higher investment in healthcare. Market players across countries are collaborating with technology providers in the United States and European countries and each other to contribute to deploying the advancement in cancer diagnosis, profiling, and treatment procedures. Furthermore, the ongoing campaigns and cancer awareness programs have highlighted the need for cancer/tumor profiling in Asian countries.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer/Tumor Profiling Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer/Tumor Profiling Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer/Tumor Profiling Market, highlighting leading vendors and their innovative profiles. These include 4basecare Onco Solutions Private Limited, ACT Genomics Co., Ltd. by Prenetics Global Limited, Agendia, Inc., Agilent Technologies, Inc., BostonGene Corporation, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GENINUS Inc., Genomic Life, GenScript Biotech Corporation, Guardant Health, Inc., Hologic, Inc., HTG Molecular Diagnostics, Inc., Illumina, Inc., IMBdx, Inc., Laboratory Corporation of America Holdings, Lucence Health, Inc., Merck KGaA, NanoString Technologies, Inc., Neogenomics, Inc., Nonacus Limited, OncoDNA S.A., Oncompass Medicine Hungary Kft., Paragon Genomics, Inc., Personalis, Inc., Perthera, Inc., Predictive Oncology Inc., Strand Life Sciences, Sysmex Corporation, Takara Bio Inc., Tempus Labs Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer/Tumor Profiling Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Immunoassays
    • In-Situ Hybridization
    • Mass Spectrometry
    • Microarrays
    • Next-Generation Sequencing
    • Polymerase Chain Reaction
  • Biomarker Type
    • Genomic Biomarker
    • Protein Biomarker
  • Cancer Type
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Melanoma Cancer
    • Prostate Cancer
  • Application
    • Biomarker Discovery
    • Clinical Application
    • Diagnostics
    • Personalized Medicine
    • Prognostics
    • Research
    • Screening
    • Treatment & Monitoring
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cancer/Tumor Profiling Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer/Tumor Profiling Market?

3. What are the technology trends and regulatory frameworks in the Cancer/Tumor Profiling Market?

4. What is the market share of the leading vendors in the Cancer/Tumor Profiling Market?

5. Which modes and strategic moves are suitable for entering the Cancer/Tumor Profiling Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of biomarkers to treat cancer patients
      • 5.1.1.2. Availability of government and global organizations' initiatives for devising cancer diagnosing methods
      • 5.1.1.3. Surging preference for personalized medicines for cancer treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High capital investment in cancer/tumor profiling instruments and services
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of next-generation sequencing and advancements in tumor profiling
      • 5.1.3.2. Improvements in point-of-care diagnostic technologies to improve cancer detection
    • 5.1.4. Challenges
      • 5.1.4.1. Low biomarker discovery-to-approval ratio
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers
    • 5.2.2. Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation
    • 5.2.3. Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification
    • 5.2.4. Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time
  • 5.3. Market Trend Analysis
    • 5.3.1. Government initiatives for cancer diagnostics with rapid advancements in cancer/tumor profiling solutions
    • 5.3.2. Rising cancer prevalence with evolving cancer research initiatives enhancing the need for novel cancer/tumor profiling in the APAC region
    • 5.3.3. Increasing adoption of precision medicines and genetic profiling solutions to overcome the cancer burden across EMEA region
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis

6. Cancer/Tumor Profiling Market, by Technology

  • 6.1. Introduction
  • 6.2. Immunoassays
  • 6.3. In-Situ Hybridization
  • 6.4. Mass Spectrometry
  • 6.5. Microarrays
  • 6.6. Next-Generation Sequencing
  • 6.7. Polymerase Chain Reaction

7. Cancer/Tumor Profiling Market, by Biomarker Type

  • 7.1. Introduction
  • 7.2. Genomic Biomarker
  • 7.3. Protein Biomarker

8. Cancer/Tumor Profiling Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Breast Cancer
  • 8.3. Colorectal Cancer
  • 8.4. Lung Cancer
  • 8.5. Melanoma Cancer
  • 8.6. Prostate Cancer

9. Cancer/Tumor Profiling Market, by Application

  • 9.1. Introduction
  • 9.2. Biomarker Discovery
  • 9.3. Clinical Application
  • 9.4. Diagnostics
  • 9.5. Personalized Medicine
  • 9.6. Prognostics
  • 9.7. Research
  • 9.8. Screening
  • 9.9. Treatment & Monitoring

10. Americas Cancer/Tumor Profiling Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cancer/Tumor Profiling Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cancer/Tumor Profiling Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Agilent and NCCS Sign Research Collaboration Agreement to Advance Singapore's Genomic Profiling on Asian-prevalent Cancers
    • 13.3.2. Sophia Genetics, Agilent Partner on Cancer Analysis Product
    • 13.3.3. Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer
    • 13.3.4. Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution
    • 13.3.5. Exact Sciences Launches OncoExTra Cancer Therapy Selection Test in the U.S.
    • 13.3.6. Caris Life Sciences nears USD 2B in total funding with USD 400M haul
    • 13.3.7. Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco
    • 13.3.8. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
    • 13.3.9. Prenetics Acquires ACT Genomics
    • 13.3.10. Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for Enhertu
    • 13.3.11. CDC Awards USD 215 Million to Advance Cancer Moonshot Goals

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CANCER/TUMOR PROFILING MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER/TUMOR PROFILING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CANCER/TUMOR PROFILING MARKET DYNAMICS
  • FIGURE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. CANCER/TUMOR PROFILING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. CANCER/TUMOR PROFILING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER/TUMOR PROFILING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IN-SITU HYBRIDIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IN-SITU HYBRIDIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENOMIC BIOMARKER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENOMIC BIOMARKER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEIN BIOMARKER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEIN BIOMARKER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MELANOMA CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MELANOMA CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SCREENING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SCREENING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TREATMENT & MONITORING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TREATMENT & MONITORING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 100. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 120. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 127. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 128. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 129. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 136. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 137. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 142. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 143. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 144. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 145. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 152. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 153. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 158. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 159. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 160. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 161. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 166. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 168. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 176. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 177. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 182. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 184. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 192. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 193. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 198. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 199. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 200. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 201. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 206. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 207. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 208. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 209. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 225. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 226. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 227. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 232. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 233. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 234. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 235. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 240. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 241. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 242. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 243. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 248. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 249. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 250. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 251. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 256. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 257. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 258. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 259. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 264. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 265. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 266. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 267. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 272. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 273. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 274. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 275. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 280. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 281. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 282. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 283. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 288. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 289. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 290. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 291. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 294. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 295. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 296. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 297. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 298. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 299. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 304. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 305. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 306. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 307. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 308. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 309. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 312. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 313. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 314. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 315. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 316. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 317. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 318. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 319. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 320. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 321. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 322. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 323. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 324. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 325. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 326. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 327. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 328. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 329. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 330. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 331. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 332. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 333. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 334. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 335. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 336. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE,